WAYNE, Pa.--(BUSINESS WIRE)--May 26, 2016--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
devices for critical care, urology and surgery, is committed to
connecting clinicians with technology in a way that improves clinical
practice and advances patient outcomes. Teleflex will showcase its Arrow®
EZ-IO® Intraosseous Vascular Access System and other products
for rescue airway, atomization and intubation needs at the first
European Emergency Medical Service Congress (“EMS 2016”) to be held in
Copenhagen, Denmark, on May 30-June 1, 2016.
Achieving better treatment for the patient is the goal of this event,
which will highlight the latest knowledge on best practices and the
newest equipment in the area of emergency medical services and
pre-hospital care.
This is a perfect setting for Teleflex to focus on its Arrow® EZ-IO®
Intraosseous Vascular Access System.
The Arrow® EZ-IO® Intraosseous Vascular Access
System from Teleflex is an innovative and complete solution for rapid
vascular access – whether the emergency responder is facing difficult
vascular access challenges or the need for fast intraosseous access for
critical situations and life-threatening emergencies. This system is
designed to provide the medical professional vascular access to the
central circulation system within seconds1, delivering
medications, intravenous fluids and blood products to adult and
pediatric patients alike.
The Teleflex Clinical & Medical Affairs team will be at the booth to
conduct resuscitation scenarios on high fidelity simulation models. The
team of highly experienced clinicians will demonstrate the latest
evidence based interventions related to intraosseous needle placement.
These interactive sessions will help educate clinicians from around
Europe, improving patient outcomes through advancing clinical practice.
Teleflex will also feature the LMA® Supreme™
Airway and the LMA® MAD Nasal™ Intranasal Mucosal Atomization
Device.
The LMA® Supreme™ Airway is the market leading
second generation subglottic airway. The gastric drain tube channels
secretions away from the airway in compliance with NAP4 guidelines.
Effective first and second seal technology truly separates the digestive
tract from the airway making this the first choice subglottic airway for
emergency use.
When IV drug delivery is less than ideal, the LMA® MAD Nasal™
Device2 from Teleflex can come to the rescue, delivering
safe, painless and rapidly effective treatment. No needle. No trauma. No
risk of needle stick injury.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®
and Weck® – trusted brands united by a common sense of
purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Deknatel, EZ-IO, Hudson RCI, LMA,
LMA Supreme, MAD Nasal, Pilling, and Weck are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries. © 2016 Teleflex Incorporated. All rights
reserved.
References:
1. Von Hoff DD , Kuhn JG, Burris HA, Miller LJ. Does intraosseous equal
intravenous? A pharmacokinetic study. Amer J Emerg Med 2008;26:31-8
2. For use with drugs approved for intranasal delivery
View source version on businesswire.com: http://www.businesswire.com/news/home/20160526005094/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836
or
Martina
Teichmann-Zindler
Director Marketing Communications International
+49
(0)7151-406-538
martina.teichmann@teleflex.com